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SUMMARY 
Malaria is a major public health problem in endemic countries, and the quality of anti-
malarial products is a concern in the therapeutic management of individual patient. In this 
study, we have evaluated the pharmaceutical quality of chloroquine and paracetamol oral 
products obtained from a major Nigerian drug “market” using a less elaborate sampling 
procedure. Results have shown that there are still some defects in the pharmaceutical quality 
of these drugs, despite the activities of the Nigeria’s drug regulatory agency (National agency 
for Food and Drug Administration and Control, NAFDAC).  21% (7/34) of the drug 
products were not registered by NAFDAC. The pharmaceutical properties of the products 
indicated that 6, 15, 9, and 9% of them failed tests for disintegration, dissolution, crushing 
strength, and percentage of active content, respectively. 4 out of the 6 chloroquine liquid 
preparations evaluated had inadequate active content.  These defects could have resulted 
from deliberate counterfeiting, poor quality control during manufacture or decomposition of 
the products. However, this could not be ascertained from the data available to us in this 
study. The implication of these findings, however, is that the newer anti-malarial drugs that 
have recently been introduced into the Nigerian market should be safeguarded, if their 
therapeutic usefulness must be sustained.  
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Introduction 
 Malaria is one of the most important parasitic 
diseases in Nigeria and several other tropical and 
sub-tropical countries of the world. The global 
burden of the disease stands at 300 – 500 million 
clinical cases and over a million deaths per year [1]. 
In addition, huge economic losses are associated with 
the disease, particularly in sub-Saharan Africa where 
over 90% of malaria cases are said to occur [2]. In 
Africa, case management of malaria is one of the 
most frequently used anti-malarial interventions, 
despite the documented evidence of other preventive 
measures such as prevention of the contact between 
humans and vectors [1]. Until recently, chloroquine 
was the first line drug in the management of malaria 
in Nigeria and several other countries where the 
disease is endemic, because it is cheap and affordable 
[3]. In addition, chloroquine is often used as anti-
malarial prophylaxis for pregnant women, sickle cell  
 
anaemic patients and semi-immune and non-immune 
individuals [3]. Paracetamol is frequently used in 
addition to chloroquine or other anti-malarial drugs 
for the management of fever associated with malaria 
because of its antipyretic activity.  
          However, one of the most important challenges 
in the chemotherapy of malaria and other infectious 
diseases in less developed countries, where these 
diseases are of immense public health importance, is 
the wide scale availability of fake and substandard 
drug products [4]. Substandard drugs contribute to 
the spread of drug-resistant malaria parasites and may 
lead to increasing therapeutic failure and medical 
expense [5]. An earlier study by Taylor et al on the 
pharmacopoeial quality of some essential drugs 
purchased from two Nigerian urban cities (Lagos and 
Abuja) showed a high prevalence of substandard 
products [6]. More than 50% of anti-malarial drugs 
were found not to have complied with the 
specifications of British Pharmacopoeia (BP) [6]. The 
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study was undertaken prior to the commencement of 
efforts by the nation’s National Agency for Food 
Administration and Control (NAFDAC) to rid the 
country of fake and substandard products. 
Nevertheless, to the best of our knowledge, no 
systematic study has yet assessed the impact of 
NAFDAC efforts in this regard. We, therefore, 
undertook this study as part of a proposed large scale 
study of the quality of anti-malarial drugs in 
circulation in Nigeria and its implications in 
achieving global targets of effective malarial 
intervention in the country. The objective of this 
study was to evaluate pharmaceutical quality of 
chloroquine and paracetamol sourced from a major 
Nigerian drug “market”. Chloroquine and 
paracetamol were chosen as the study drugs because 
of their ready availability and use in the country. It 
has been reported that drug counterfeiting is most 
commonly associated with “fast moving” 
pharmaceutical products [7]. 
 
Materials and Methods 
Drug sampling: On a cross-sectional basis, 
chloroquine and paracetamol tablets (10 brands each) 
and syrups (6 brands of chloroquine and 8 brands of 
paracetamol) were purchased in February, 2004 from 
the market (pharmacies and shops) in Onitsha and a 
neighbouring town of Asaba, Nigeria, by one of the 
investigators (JOO) with the assistance of two other 
persons. The study location was chosen because we 
envisaged that it may give a better refection of the 
situation in the country. Drug faking has been linked 
to “open” drug markets in some major cities in 
Nigeria, one of which is located in Onitsha. No 
particular sampling procedure was employed, other 
than the buyers posing as “normal” customers to 
purchase the drugs without prescription. The different 
brands and formulations of the two drugs were 
sourced from drug stores wherever they were 
available, until the total number was obtained. 
Following purchase, information on brand, 
manufacturer, NAFDAC registration status and 
expiry date were recorded from the product label. No 
attempt was made to verify these information. 
Drug testing: Pharmaceutical properties, including 
organoleptics (colour, texture, smell and taste), and 
physicochemical properties (weight, drug content and 
identification, as well as tablet crushing strength, 
disintegration and dissolution) were determined. 
Organoleptic properties were determined (after 
pulverization in the case of tablets), and examined for 
colour, texture smell and taste. A panel of six persons 
who were blinded to source and manufacturer of the 
drugs carried out the examination, and a majority 
verdict was taken. Assay of chloroquine and 
paracetamol contents of the dosage forms were also 
carried out. Chloroquine was assayed using a 
validated non-aqueous method [8], while paracetamol 
was assayed using a validated spectrophotometric 
method. All procedures, including pH determination, 
were carried out in duplicate and in accordance with 
the British Pharmacopoeia 1993 [8]. 
 
Results  
A total of 34 samples of chloroquine and paracetamol 
phosphate products were analysed. All samples were 
within shelf life at the time of the study, with an 
exception of one product (CL14). Twenty one 
percent (7/34) of the drug products were not 
registered by NAFDAC. Of these unregistered 
products, 5 were chloroquine and 2 were paracetamol 
(Table 1).  The organoletic properties indicated that 
chloroquine and paracetamol tablets were in 
conformity with BP standards, and did not vary 
between country of origin (Tables 2 and 3).  Results 
of assessment of the physicochemical properties of 
the tablet preparations showed that the disintegration 
of chloroquine tablets ranged from 2.33 minutes to 
32.75 minutes, with an average of 6.27 (locally 
produced) and 15.03 (“imported” products). Two 
“imported” products, CS6 and CS8 failed the test. 
Also, there was a tendency for the “imported” 
products to have high disintegration time as 
compared to locally produced chloroquine. 
Percentage dissolution within 45 minutes gave values 
that ranged from 45.51 to 104.30, with only one 
product, CS6 having percentage dissolution in 45 
minutes of less than the 70% minimum stipulated by 
the BP. The content of chloroquine tablets was found 
to be within normal range, except for one imported 
product, CS6, which had a percentage of the stated 
amount of 116.5%, a value outside the BP range of 
92.5 – 107.5% (Table 4).  
              The disintegration time for all paracetamol 
tablets were within the pharmacopoeial range (≤15 
min), while percentage tablet dissolution of the drug 
in 45 minutes ranged from 64.26 to 73.06, with four 
products (PS 3, 4, 5 and 7) failing the test. In terms of 
percentage of stated amount, two products, PS1 and 
PS8, were found to be outside the pharmacopoeial 
range (95 to 105%) for paracetamol (Table 5). There 
is no pharmacopoeial requirement for tablet crushing 
strength, but in industrial practice, 4kg is generally 
considered a minimum. The crushing strengths for 
chloroquine and paracetamol tablets were found to be 
within 7.34 to 13.32 kg and 1.91 to 7.28kg, 
respectively. Three chloroquine products, (all locally 
produced, CS1, CS2 and CS3) did not conform to the 
requirement. 
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Table 1.0: Description of chloroquine and paracetamol tested for pharmaceutical properties. 
        Type of   
formulaton 
  Date of  
manufacture 























CS1   Tablet 
CS2   Tablet  
CS3   Tablet 
CS4   Tablet 
CS5   Tablet 
CS6   Tablet 
CS7   Tablet 
CS8   Tablet 
CS9   Tablet 
CS10 Tablet 
CL11  syrup 
CL12  syrup 
CL13  syrup 
CL14  syrup 
CL15  syrup 






















































































PS1   Tablet 
PS2   Tablet 
PS3   Tablet 
PS4   Tablet 
PS5   Tablet 
PS6   Tablet 
PS7   Tablet 
PS8   Tablet 
PS9   Tablet 
PS10 Tablet 
PL11  syrup 
PL12  syrup 
PL13  syrup 
PL14  syrup 
PL15  syrup 
PL16  syrup 
PL17  syrup 














































































All liquid preparations of chloroquine and 
paracetamol were packaged in amber colour bottle 
with an exception of one, CL15, which was packaged 
in a white 2L container. Other pharmaceutical 
properties of chloroquine and paracetamol liquid 
preparations are shown in Tables 6 and 7. None of 
the chloroquine syrups and only three paracetamol 
syrup products (PL11, 12 and 13) met the BP 
requirements for pH.  
Discussion  
Traditionally, the problem of counterfeit 
pharmaceuticals has been limited to developing 
nations in Asia and Africa. Now, drug counterfeiting 
is rapidly becoming a worldwide concern, and 
counterfeit drugs are beginning to reach the advanced 
markets [9]. Though artemisinin-based combination 
drugs have been officially adopted by the Federal 
Government of Nigeria as the first line anti-malarial 
drugs, a majority of health care providers and 
consumers in the country still prefer to use 
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chloroquine because it is very affordable. They 
contend that the real problem with chloroquine 
chemotherapy is the widespread faking of the product 
resulting in suboptimal therapeutic response.  
                                        
              Table 2: Organoleptic characteristics of chloroquine tablets 
                                                                                                                                                  
Assigned codes                                                                                              
                                           Appearance                         Taste                                                                    
Chloroquine tablet 
  Locally produced 
   CS1                            Milky white round                Intensely bitter                                 
   CS2                            Whitish round                       Intensely bitter                                  
   CS3                            Whitish round                       Intensely bitter                                          
   CS4                            Milky yellow                          Intensely bitter                                  
   CS5                           Off white                                Intensely bitter                                  
 
“Imported” 
  CS6                              Milky round                           Intensely bitter 
  CS7                              Whitish round                       Intensely bitter  
  CS8                              Milky white                           Intensely bitter   
  CS9                              White round film coated       Intensely bitter   
  CS10                            Whitish round                       Intensely bitter 
       
          
                Table 3.: Organoleptic characteristics of paracetamol tablets 
                                                                                                                                                     
Assigned codes                                                                                              
                                        Appearance                                                  Taste                                                
Locally produced 
   PS1                            Round off white  with minting odour        Slightly bitter                                         
   PS2                            Round milky white   odourless                  Slightly bitter                                         
   PS3                            Oblong off white  odourless                      Slightly bitter                                         
   PS4                            Round milky white   odourless                  Slightly bitter                                         
   PS5                            Round milky white odourless                    Slightly bitter                                         
“Imported” 
  PS6                             Oblong off white   odourless                     Slightly bitter 
  PS7                             Round off white    odourless                     Slightly bitter 
  PS8                             Round off white    odourless                     Slightly bitter 
  PS9                             Round off white    odourless                     Slightly bitter  
  PS10                           Round cream       odourless                       Slightly bitter 
 
Table 4:  Physicochemical characteristics of chloroquine tablets 
 Assigned code                      DT(mins)            D45mins                 W                           DC (PA )         
Chloroquine tablet 
  Locally produced  
   CS1                                   2.58                  95.70(11.04)       428.0 (2.3)             264.14 (105.65)      
   CS2                                    3.83                 102.36(6.28)       309.0 (2.3)             249.6 (99.8)            
   CS3                                    2.33                 102.2 (3.50)        324.0 (2.8)             249.58 (99.83)        
   CS4                                   13.08                94.60(3.62)         304.0 (6.3)             245.42 (98.17)        
   CS5                                   9.23                  98.18(7.01)         307.02 (2.1)           246.14 (105.65)     
 Average                              6.27                   98.61                  334.4                     251.0   (101.82)                         
“Imported” 
  CS6                                    32.75                45.51(7.33)          313.0 (2.5)            291.2 (116.5) 
  CS7                                    13.83                102.30(8.11)       298.0 (4.0)             268.3 (107.32) 
  CS8                                    16.17                102.32(4.44)        367 (1.9)                259.98 (103.99) 
  CS9                                    11.20                104.30(9.54)        305 (2.3)                260.05 (104.00) 
  CS10                                   5.28                 100.12(6.01)       348.0 (2.3)              252.7 (101.08) 
 Average                              15.03                 90.91                  326.2                      266.4 (106.58) 
 
DT = disintegration time, D45mins = percentage dissolution in 45 minutes, W = average weight per tablet,  
DC = drug content, PA = percentage of label strength, 
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Table 5:  Physicochemical characteristics of paracetamol tablets 
 Assigned code                      DT(mins)                 D45mins                  W                   DC (PA )         
Paracetamol tablet 
Locally produced 
  PS1                                     0.83                    72.50 (10.59)        554 (3.4)            555.7(111.14)         
  PS2                                     7.17                    72.28 (12.99)        590 (3.4)            477.9 ( 95.6)           
  PS3                                     4.33                    64.26(11.41)         587 (1.2)            502.6 (100.5)          
  PS4                                     0.75                    69.81(2.47)           551 (3.6)           493.2 (98.64)        
  PS5                                     5.67                     69.81(2.47)           552 (3.1)           503.5 (100.7)         
 Average                               3.70                    69.67                     566.80               506.58 (101.32)                         
“Imported” 
  PS6                                    1.7                       73.06(11.08)          610 (5.2)           482.95 (96.6) 
  PS7                                     7.42                    66.21(11.25)          575  (2.9)          467.5 (96.6)  
  PS8                                    2.08                    72.67(96)                605 (1.2)          558.8 (112.0)                             
  PS9                                    2.87                    70.02(10.24)           621 (1.6)          427.1 (94.4) 
  PS10                                  1.5                      80.09(27.14)           587 92.0)         481.1 (96.22) 
  Average                             3.57                    72.41                      599.60             483.49 (98.54) 
 
DT = disintegration time, D45mins = percentage dissolution in 45 minutes, W = average weight per tablet,  
DC = drug content, PA = percentage of label strength 
 
While it may be understood that counterfeit anti-
malarial drugs pose a great threat to the lives of 
patients with malaria [10], it has not be possible to 
consistently evaluate the prevalence of substandard 
drugs in circulation, especially in the less developed 
countries. Also, in spite of the fact that international 
organisations such as the World Health Organization, 
have devised specific measures to combat counterfeit 
trade, the problem still remains quite daunting. 
Furthermore, although the practice of drug 
counterfeiting is unlikely to ever completely 
disappear, it may be controlled if governments and all 
relevant parties combine forces to identify and 
disrupt the counterfeit chain [11]. Poor quality of 
medicinal products could result from poor quality 
control of drugs during manufacture, chemical 
instability due to hot climatic condition and outright 
faking of medicines [6].      
         This study evaluated NAFDAC registration 
status, product stocking beyond expiration date, 
organoleptic and physicochemical properties of two 
products, which were sourced from the Nigerian 
market, and are important in the chemotherapy of 
malaria. Physicochemical properties are important 
considerations in solid dosage form. For example, 
disintegration measures the time required for tablets 
to disintegrate into particles prior to dissolution. 
British Pharmacopoeia (1993) [8] stipulates a time of 
not more than 15 minutes (uncoated tablets) and 30 
minutes (capsules). The results showed that all 
paracetamol products tested passed the requirement, 
while two “imported” brands of chloroquine failed to 
meet the specification. Dissolution on the other hand 
measures the release characteristics of active 
ingredients in vitro from solid dosage form. It gives a 
fair indication of drug absorption into the systemic 
circulation in order to exert its pharmacologic and 
clinical effects. The BP (1993) specifies that at 45 
minutes all tablets and capsules should release an 
amount not less than 70% of the label claim into the 
dissolution medium. Four paracetamol products and 
one chloroquine product, CS6, failed to meet the 
specification. Poor formulation, especially the type 
and/or quantity of excipients may affect 
disintegration and dissolution characteristics of solid 
dosage form. However, this was not investigated in 
this study.  
         The crushing strength of tablets measures its 
ability to resist chipping, abrasion or breakage during 
storage, transportation and handling. Failure in 
crushing strength of pharmaceutical solid dosage 
form could result from inadequate binding agent 
during formulation or insufficient compression 
during tableting. Findings from this study indicate 
that 85% of the solid dosage forms passed the test; 
the products that failed the test were locally 
produced. 
         The Pharmaceutical Codex [12] stipulates that 
for maximum stability, the pH of liquid chloroquine 
and paracetamol preparations should be within 4.2 to 
5.0 and 5 to 7, respectively.  The results show that 
none of the liquid chloroquine preparations passed 
the test, while only 50% of the liquid paracetamol 
products conform to the specification (Table 6). 
Furthermore, 4 out of the 6 chloroquine liquid 
preparations evaluated had inadequate active content. 
In fact, no active ingredient was found in one of the 
products, CL15 (Table 7). The implication of this is 
that when such products are given, the patient might 
fail to show adequate clinical response.     
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     Table 6: Organoleptic characteristics of chloroquine and paracetamol liquid preparations 
 
       
      
       Table 7:  Physicochemical characteristics of chloroquine and paracetamol liquid products 
                                                                                                                                         
 Assigned code             LS               Actual content/5ml (% label strength) 
                                
Chloroquine syrup 
  CL11                          80                                   64.7 (80.87)      
  CL12                          80                                   77.9 (97.38) 
  CL13                          80                                   70.31(87.90) 
  CL14                          80                                   61.30 (76.63) 
  CL15                          80                                   Nil ( 0.00) 
  CL16                          80                                   85.82 (107.28) 
Paracetamol syrup 
  PL11                        120                                  118.82 (99.02)          
  PL12                        120                                  122.28 (101.91)       
  PL13                        125                                  123.6 (98.88) 
  PL15                        125                                  117.63 (94.10) 
  PL17                        125                                  123.25 (98.60) 
  PL18                        125                                  41.72 (113.38) 
  PL14*                       120                                 93.98  (78.32) 
  PL16*                       125                                 112.75 (90.20) 
 
 
      LS = label strength, *are imported liquid paracetamol products 
 
Conclusion 
Despite the concerted efforts by NAFDAC in 
ensuring that safe and effective drugs are in  
 
circulation in the country, this study has shown that 
there are still some defects in the pharmaceutical 
Assigned codes          Appearance            Taste                                pH 
Chloroquine syrup 
  
  CL11                                Light pink                       Bitter                                         2.42                              
  CL12                                Bright yellow                  Bitter                                         2.67 
  CL13                                Dark pinkish                   Bitter                                         2.45 
  CL14                                Golden yellow                Bitter                                         2.73 
  CL15                                Pinkish                           Bitter                                         6.98 




 “Locally” produced   
  PL11                               Pinkish elixir                     Minty sweet                             4.71         
  PL12                               Light pinkish   syrup         Pineapple sweet                       4.03                                   
  PL13                               Pinkish syrup                    Sweet                                       4.01 
  PL15                               Pinkish elixir                     Characteristics and minty        5.25                                   
  PL17                               Pinkish syrup                    Sweet with some bitter taste    5.14                                    
  PL18                               Pinkish syrup                    Characteristic  sweet                5.01 
                                                                                   
“Imported” products 
PL14                                 Pink viscous suspension    Very sweet                              5.07 
PL16                                 Light pink suspension        Slightly sweet                         5.12 
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quality of chloroquine and paracetamol sold in 
Nigeria. A number of the products fell below the 
regulatory standards irrespective of the country of 
origin. Whether these defects result from deliberate 
counterfeiting, poor quality control during 
manufacture or decomposition of the products could 
not be ascertained. However, findings from the study 
serve as signals for newer anti-malarial drugs (e.g. 
artemisinin-based combination drugs) that were 
recently introduced into the Nigerian market. It is 
important that these products are safeguarded in order 
to prolong their therapeutic usefulness. Availability 
of safe and effective anti-malarial drugs is one 
strategy aimed at attaining the United Nations’ 
malaria-related Millennium Development Goals. 
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